1994]. Gründer and colleagues stated that amisulpride treatment elevated TSH levels in both male and female patients and GH levels only in females [Gründer et al. 1999]. In our study, we assessed TSH, free T3, free T4, GH, ACTH, cortisol and sex hormones and found no significant difference in their levels with amisulpride treatment. We found no QT prolongation or any other Inhibitors,research,lifescience,medical abnormality in electrocardiograms of patients during amisulpride treatment consistent with the findings of Rein and colleagues [Rein et al. 2000].
Our study is limited since it was an open-label study with a small sample size and did not have a control group. However, we think that the present study will contribute to the literature as there is only Inhibitors,research,lifescience,medical a very limited number of studies investigating endocrinologic, metabolic and cardiac effects of amisulpride. In conclusion, the clinical data from the present study supports the fact that amisulpride indicates several advantages for long-term use. The results of long-term clinical trials concur in demonstrating its efficacy against both positive and negative symptoms of schizophrenia. Amisulpride has a relatively low propensity to induce EPS compared Inhibitors,research,lifescience,medical with conventional antipsychotics and is associated with a lower
risk of metabolic syndrome and cardiac dysfunction than some of other SGAs. The principle side effects appear to be associated with hyperprolactinemia with much higher prolactin levels in women. However, these side effects were subtle
in our patient group. To the best of the authors’ knowledge, this study is the first to investigate many metabolic, endocrinologic and cardiac effects of amisulpride together in a 24-week follow-up period. Future studies Inhibitors,research,lifescience,medical with larger samples will help us to understand clinical and biochemical aspects of this unique molecule further. This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. The authors have no conflicts of interest related to this study.
HTS assay Background: Clozapine is the most effective for antipsychotic in Inhibitors,research,lifescience,medical treatment-resistant schizophrenia but its use portends with a high burden of adverse reactions. One adverse event reported both in case reports and cross-sectional surveys is the emergence or worsening of obsessive compulsive symptoms (OCS). Objectives: This study presents a retrospective review of a UK cohort of clozapine-treated individuals with the aim to further investigate the complex relationship between clozapine and OCS. Methods: An extensive review of the medical records of 49 patients receiving clozapine in the Southampton area was undertaken. We searched for a diagnosis of obsessive compulsive disorder, signs or symptoms of obsessive compulsive disorder or the prescribing of selected antidepressants the year before clozapine initiation and the year after.